Clinical Trial Results:
            Efficacy and safety of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® (glutaraldehyde-polymerized allergen extract of mixtures of grass and rye allergens – Holcus lanatus, Dactylis glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca elatior, Secale cereale) in patients with allergic rhinoconjunctivitis sensitized to grass and with or without rye pollen sensitization. A prospective, double-blind, randomized, placebo-controlled, multi-centre trial.
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2008-000513-29 | 
    Trial protocol  | 
        DE | 
    Global completion date  | 
        
                                    02 Dec 2009
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    15 Sep 2021
                             
         | 
    
    First version publication date  | 
        
                                    15 Sep 2021
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                Klimek et al. Allergy 2014 | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.